Forbes Norris MDA/ALS Research Center

A second ALS lithium trial is ended after an interim analysis revealed no benefit and possible toxicity

posted on November 6, 2009 - 10:00pm
An Italian trial to test the effects of lithium carbonate in amyotrophic lateral sclerosis (ALS) has ended before its originally scheduled completion date because of an unusually high number of dropouts, lack of demonstrated benefit, and concerns about the drug's possible toxicity.

New content is being added every day. Please check back again.